Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020
Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Source: Eur Respir J, 55 (6) 2000041; 10.1183/13993003.00041-2020 Year: 2020
Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020
Gas transfer relates to pulmonary haemodynamics and survival in pulmonary arterial hypertension associated with systemic sclerosis Source: Eur Respir J 2007; 30: Suppl. 51, 344s Year: 2007
Identifying early pulmonary arterial hypertension in patients with systemic sclerosis Source: Eur Respir J, 51 (4) 1800495; 10.1183/13993003.00495-2018 Year: 2018
A potential role for sildenafil in the management of pulmonary hypertension associated with parenchymal lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006
Bosentan for sarcoidosis associated pulmonary arterial hypertension (BoSAPH) was effective in advanced parenchymal lung disease Source: Annual Congress 2012 - Sarcoidosis Year: 2012
Impact of long-term oxygen therapy on systemic inflammation, morphological changes of red blood cells, pulmonary hemodynamics and diaphragm function in patients with chronic obstructive pulmonary disease. Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD Year: 2018
Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry Source: Eur Respir J, 58 (2) 2101483; 10.1183/13993003.01483-2021 Year: 2021
Clinical characteristics, haemodynamics, and survival in patients with combined pulmonary fibrosis and emphysema and associated pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular medicine Year: 2008
Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening Source: Eur Respir Rev 2011; 20: 270-276 Year: 2011
Hemodynamic phenotypes in systemic sclerosis patients screened for pulmonary hypertension – impact of the new PH-definition Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019
Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension Source: Eur Respir J, 52 (4) 1800678; 10.1183/13993003.00678-2018 Year: 2018
Pulmonary arterial hypertension associated with sarcoidosis (BBS-PAH): mechanisms, hemodynamics and prognosis Source: Eur Respir J 2002; 20: Suppl. 38, 371s Year: 2002
Differences between limited and diffuse systemic sclerosis-related pulmonary arterial hypertension Source: Annual Congress 2011 - Clinical features of pulmonary hypertension Year: 2011
Bosentan influence on cellular immunity parameters in patients with idiopathic arterial pulmonary hypertension Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012
Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis Source: Eur Respir J 2016; 48: 1658-1667 Year: 2016
Oxygen pulse slope analysis during exercise testing identifies patients with systemic sclerosis at a possible risk for developing pulmonary vasculopathy Source: Annual Congress 2013 –Clinical exercise physiology Year: 2013
Histopathology of idiopathic pulmonary arterial hypertension in patients with low or normal diffusion capacity Source: Annual Congress 2012 - Pulmonary circulation: clinical end-points and clinical physiology Year: 2012
Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation Source: Eur Respir J 2014; 43: 1306-1315 Year: 2014